List view / Grid view

Eli Lilly and Company

Jardiance^® improves blood sugar control in type 2 diabetes

7 December 2022 | By Catherine Eckford (European Pharmaceutical Review)

A Phase III trial showed Jardiance® is the first SGLT2 inhibitor to significantly reduce average blood sugar in type 2 diabetics aged 10-17 compared to placebo.

news

Empagliflozin reduces risk of chronic kidney disease progression

7 November 2022 | By Catherine Eckford (European Pharmaceutical Review)

A major trial evaluating Boehringer Ingelheim’s Jardiance®, showed it reduced the risk of cardiovascular death and chronic kidney disease progression by 28 percent.

news

Lilly will acquire Akouos to accelerate hearing loss therapies

19 October 2022 | By Catherine Eckford (European Pharmaceutical Review)

Eli Lilly and Company’s $610 million acquisition of Akouos will fast-track gene therapies that restore, improve and preserve hearing for patients worldwide.

3D illustration of Medicine capsule showing its active ingredients

news

HPAPI market to value $27bn by 2025

8 June 2022 | By Hannah Balfour (European Pharmaceutical Review)

Driven by oncology drug demand, the highly potent active pharmaceutical ingredients (HPAPIs) market is anticipated to grow by $7bn in three years.

news

Lilly to build two new US manufacturing sites

31 May 2022 | By Hannah Balfour (European Pharmaceutical Review)

Eli Lilly and Company announces plans to establish two new manufacturing facilities in Indiana USA worth $2.1 billion.

news

Eli Lilly shares impressive hair regrowth results with Olumiant^® for alopecia

30 March 2022 | By Mandy Parrett (European Pharmaceutical Review)

The results of Eli Lilly and Company’s double-blind, placebo-controlled Phase III trials for Olumiant® are encouraging for patients suffering with alopecia.

news

Empagliflozin trial halted after successful outcome in chronic kidney disease

21 March 2022 | By European Pharmaceutical Review

An early halt has been called to a major kidney drug trial following positive results for patients with chronic kidney disease (CKD).

news

Empagliflozin benefits adults hospitalised for acute heart failure, shows study

4 March 2022 | By European Pharmaceutical Review

Phase III trial shows that adults hospitalised for acute heart failure were 36 percent more likely to experience a clinical benefit if initiated on empagliflozin.

blue and clear capsule with a silver DNA stand inside - idea of gene therapy

news

Lilly to create $700mn Institute for Genetic Medicine

23 February 2022 | By Hannah Balfour (European Pharmaceutical Review)

Investing $700mn to establish a new site, Eli Lilly plans to fuel the development of genetic medicines through the company’s new Institute for Genetic Medicine.

news

Lilly to build new $1bn manufacturing facility in US

31 January 2022 | By Hannah Balfour (European Pharmaceutical Review)

The new North Carolinian site will increase parenteral and device manufacturing capacity and create 600 new jobs.

news

ProQR and Lilly collaborate to develop RNA therapeutic

9 September 2021 | By Anna Begley (European Pharmaceutical Review)

ProQR and Lilly announced a collaboration to combat genetic disorders in the liver and nervous system using Axiomer® RNA editing platform.

news

Lilly to collaborate with Lycia on novel protein degraders

26 August 2021 | By Hannah Balfour (European Pharmaceutical Review)

The collaborators will use Lycia’s lysosomal targeting chimera (LYTAC) protein degradation platform to develop therapies for five targets across Lilly’s therapeutic areas of focus.

news

FDA approves Jardiance^® for heart failure with reduced ejection fraction

19 August 2021 | By Anna Begley (European Pharmaceutical Review)

The FDA have approved Lilly’s Jardiance (empagliflozin) to treat adults living with heart failure with reduced ejection fraction.

news

Lilly announces leadership changes and creation of new business units

18 August 2021 | By Anna Begley (European Pharmaceutical Review)

Eli Lilly and Company have announced executive leadership changes and the creation of neuroscience and immunology business units.

news

Lebrikizumab displays 75 percent skin clearance in dermatitis patients

16 August 2021 | By Anna Begley (European Pharmaceutical Review)

Lebrikizumab achieved at least 75 percent skin clearance in more than half of patients with atopic dermatitis (AD), shows Phase III study.

Cookie	Description
cookielawinfo-checkbox-advertising-targeting	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics	This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance	This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID	This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged	This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.

Cookie	Description
cf_ob_info	This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob	This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only	This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush	This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db	This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC	This cookie is set by Youtube and is used to track the views of embedded videos.

Cookie	Description
bcookie	This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS	This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang	This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc	This cookie is set by LinkedIn and used for routing.
lissc	This cookie is set by LinkedIn share Buttons and ad tags.
vuid	We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId	This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule	This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session	This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues	This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga	This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat	This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid	This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.

Cookie	Description
advanced_ads_browser_width	This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions	This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info	This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer	This cookie is set by Advanced Ads and sets the referrer URL.
bscookie	This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE	This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr	This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory	This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE	This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.

Recommended

Eli Lilly and Company